BHV-2100
Undisclosed
Key Facts
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a mission to discover, develop, and commercialize life-changing therapies for severe diseases. Its most significant achievement was the discovery, approval, and subsequent $11.6 billion divestiture of its CGRP migraine franchise (Nurtec® ODT, Zavzpret®) to Pfizer in 2022, which provided substantial capital to fund its next-generation pipeline. The company's strategy is to leverage its proven drug development expertise and three proprietary technology platforms—glutamate modulation, myostatin inhibition, and Kv7 targeting—to build a diversified portfolio targeting large neurological and rare disease markets. Biohaven's 'patient-first' culture and non-hierarchical structure are designed to drive urgency and efficiency in clinical execution.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| Amgen Collaboration Program | Xeris Biopharma | Pre-clinical |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |